Changes were observed in the ultrastructure of the pancreatic acinar cells in rats after administration of atorvastatin (Sortis) in the therapeutic and ten times larger dose for the period of 6 weeks. It was found that atorvastatin given to rats in the therapeutic dose (80 mg/day) stimulated the secretion in pancreocytes, whereas the ten times higher dose of atorvastatin distorts the complicated process of the release of the secretion from the cell.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization of two new degradation products of atorvastatin calcium formed upon treatment with strong acids.
Beilstein J Org Chem
September 2019
Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University Munich, Butenandtstr. 5-13, 81377 Munich, Germany.
Atorvastatin calcium (Lipitor, Sortis) is a well-established cholesterol synthesis enzyme (CSE) inhibitor commonly used in the therapy of hypercholesterolemia. This drug is known to be sensitive to acid treatment, but only little data has been published on the structures of the degradation products. Here we report the identification of two novel degradation products of atorvastatin, which are formed only under drastic acidic conditions.
View Article and Find Full Text PDF[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on antioxidative enzymatic activity].
Wiad Lek
February 2006
Z Katedry Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej, Uniwersytetu Medycznego, Lodzi.
The effect of atorvastatin and fluvastatin on antioxidative enzymatic activity was studied in CHD risk patients. The study comprised 35 patients (20 men and 15 women) aged 35-47 years, who were allotted into two groups: I--18 patients were administered fluvastatin (Lescol) in a dose of 40 mg once daily at bed time for 6 weeks and II--17 patients were administered atorvastatin (Sortis) in a dose of 10 mg once daily at bed time for 6 weeks. The control group consisted of 12 clinically healthy subjects, aged 34-42 years.
View Article and Find Full Text PDFHigh doses of atorvastatin (Sortis) modify the secretory process in the exocrine portion of the pancreas.
Ann Univ Mariae Curie Sklodowska Med
September 2005
Department and Institute of Histology and Embryology, Skubiszewski Medical University of Lublin.
Changes were observed in the ultrastructure of the pancreatic acinar cells in rats after administration of atorvastatin (Sortis) in the therapeutic and ten times larger dose for the period of 6 weeks. It was found that atorvastatin given to rats in the therapeutic dose (80 mg/day) stimulated the secretion in pancreocytes, whereas the ten times higher dose of atorvastatin distorts the complicated process of the release of the secretion from the cell.
View Article and Find Full Text PDF[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
Med Klin (Munich)
September 2004
European Center of Pharmaceutical Medicine, Basel, Schweiz.
Background And Purpose: Cardiovascular diseases are the leading cause of death in Germany and have a huge impact on the resource consumption. Therefore, cost-effectiveness of medical therapies must be evaluated and taken into consideration. The purpose of this study is to assess the short-term healthcare costs associated with intensive lipid lowering with atorvastatin (Sortis, Pfizer) initiated within 24-96 h after the onset of acute coronary syndromes (ACS) in patients from Germany.
View Article and Find Full Text PDFShort-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
CNS Drugs
April 2004
Department of Neurology, University of Pecs School of Medicine, Pecs, Hungary.
Introduction And Objective: Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial effects may involve lipid-independent mechanisms. The aim of this study was to assess the short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial dysfunction in patients with chronic cerebrovascular disease and hyperlipidaemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!